Latest Diabetes management Stories

OTTAWA, Ontario, May 30, 2012 /PRNewswire/ -- UBM TechInsights and Espicom Business Intelligence have joined together to publish an industry first report that combines market and intellectual property analysis on the diabetes treatment device industry. This comprehensive report (www.ubmtechinsights.com/diabetes) contains original market forecasts; detailed analysis of market and product trends, threats and opportunities; and an assessment of 5900 diabetes device patents. There...

It seems that while the practice of bloodletting throughout history had little or no effect on most diseases, and the practice was abandoned in the 19th century, new research published in BioMed Central's open access journal BMC Medicine demonstrates that blood donation has real benefits for obese people with metabolic syndrome. Two sessions of bloodletting were enough to improve blood pressure and markers of cardiovascular disease. Metabolic syndrome is the name given to a host of...

PALO ALTO, Calif. and INDIANAPOLIS, May 30, 2012 /PRNewswire/ -- Glooko, Inc., makers of an innovative diabetes logbook solution, and Roche Diabetes Care, makers of ACCU-CHEK blood glucose monitoring systems, insulin pumps and information management solutions, today announced their co-promotion of the Glooko Logbook solution in the U.S. With the introduction of the Glooko IR Adapter, ACCU-CHEK customers who prefer to manage their diabetes on their iPhone or iPod touch can now use...

RIDGEFIELD, Conn. and INDIANAPOLIS, May 29, 2012 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced they have received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of Jentadueto® (linagliptin/metformin hydrochloride) tablets, a medicine combining the DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta® tablets, marketed under the trade name Trajenta® in Europe) and...

Yale School of Medicine researchers have found that intensively controlling glucose (glycemic) levels in type-2 diabetes patients may not reduce the risk of kidney failure. The study, which is a review of data from seven clinical trials, is published in the May 28 issue of Archives of Internal Medicine. To test the hypothesis that aggressive glycemic control can prevent renal disease in patients with type 2 diabetes mellitus, first author Steven G. Coca of Yale and colleagues searched...

Aiming for & incentivizing strict BP control for all patients means some are being over-treated -- but an individualized approach could help Aggressive efforts to lower blood pressure in people with diabetes are paying off – perhaps too well, according to a new study The research shows that there have been dramatic improvements in blood pressure control among patients with diabetes in the U.S. Department of Veterans Affairs, with as many as 82 percent of patients having blood...

A review of data from seven clinical trials suggests that intensive glucose control is associated with reduced risk of microalbuminuria and macroalbuminuria (conditions characterized by excessive levels of protein in the urine usually resulting from damage to the filtering units of the kidneys), according to a report published in the May 28 issue of Archives of Internal Medicine, a JAMA Network publication. The meta-analysis also suggests the data "were inconclusive" that intensive...

American Diabetes Wholesale announces their Memorial Day Sale. Pompano Beach, FL (PRWEB) May 25, 2012 American Diabetes Wholesale announces their sale to honor Memorial Day giving customers a 10% discount on all products purchased between May 25th and May 28th at http://www.americandiabeteswholesale.com. The sale is a 4-day sale and will be applicable to all orders processed through the company’s website from May 25-28. To obtain the discount, enter coupon code MEMDAY10 into the...

RIDGEFIELD, Conn. and INDIANAPOLIS, May 24, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Phase 3 study results for linagliptin 5 mg once-daily, which showed significant hemoglobin A1c (HbA1c or A1C) reduction of 0.88 percent compared to 0.24 percent in the placebo group (p=0.0002) at 24 weeks in black or African American adult patients with type 2 diabetes whose blood sugar was not adequately controlled.[1]...

FORT WASHINGTON, Pa., May 23, 2012 /PRNewswire/ -- Nutrisystem (NASDAQ: NTRI), a leading provider of weight management products and services, today announced that it has been named a National Strategic Partner of the American Diabetes Association in recognition of its commitment to support the mission and the Association's movement to Stop Diabetes®. Nutrisystem offers the Nutrisystem® D® program, the leading home-delivered weight loss program clinically tested, in combination...